DEMETRA: Cellular-Mediated Immunity in COVID-19

Sponsor
University of Campania "Luigi Vanvitelli" (Other)
Overall Status
Recruiting
CT.gov ID
NCT04746521
Collaborator
(none)
100
1
21
4.8

Study Details

Study Description

Brief Summary

In order to prevent reinfection, it is needed to detect the cellular-mediated immune response to the Sars-CoV-2 infection. The first goal of this study will be to detect the cellular-mediated immune response in patients affected by COVID-19 (with or without vaccination) and healthy subjects who undergone vaccination program. The second goal of this study will be to identify the genetic and epigenetic biomarkers that influence individual immunological response and clinical evolution to the severe manifestations of the COVID-19.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Multitest 6 color TBNK and BD Lyotubes
  • Biological: genomicDNA extraction

Detailed Description

First goal: Characterization of the immune response using detailed phenotypic evaluation of the adaptive compartment comprising B, T, and NK cells. The Investigators aim is to detect the cellular-mediated immune response in patients affected by COVID-19 and subjects who undergone vaccination program.

The Investigators will recruit three classes of subjects:
  1. Patients with previous Sars-CoV-2 infection who did not undergo vaccination;

  2. Patients with previous Sars-CoV-2 infection who undergone vaccination;

  3. Subjects without previous Sars-CoV-2 infection who undergone vaccination.

Second goal: Evaluation of genetic and epigenetic biomarkers that influence individual immunological response and susceptibility to thromboembolic manifestations in severe COVID-19 hospitalized patients.

The Investigators will recruit:
  1. A total of 50 severe COVID-19 patients admitted to the Sub-Intensive Care Unit of A.O.R.N. Ospedali dei Colli, Cotugno Hospital, Naples (Italy) of which N=50 with thromboembolic complications (PE+) and N=50 without thromboembolic complications (PE-);

  2. A total of N=50 healthy subjects (never diagnosed with Sars-Cov2 infection) among the volunteer blood donors attending the U.O.C. Divisione di Immunologia Clinica, Immunoematologia, Medicina Trasfusionale e Immunologia dei Trapianti, Dipartimento di Medicina Interna e Specialistica, AOU, "L. Vanvitelli" University of Campania (Naples, Italy)

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
DEtection of Cellular-MEdiated immuniTy in COVID-19 Patients and Subjects Who undeRgone vAccination Program
Actual Study Start Date :
Mar 14, 2021
Actual Primary Completion Date :
Jan 14, 2022
Anticipated Study Completion Date :
Dec 14, 2022

Arms and Interventions

Arm Intervention/Treatment
Severe COVID-19 hospitalized patients

A total of 50 severe COVID-19 patients admitted to the Sub-Intensive Care Unit of A.O.R.N. Ospedali dei Colli, Cotugno Hospital, Naples (Italy) will be recruited, of which N=50 with thromboembolic complications (PE+) and N=50 without thromboembolic complications (PE-) balanced for age and sex of individuals.

Biological: genomicDNA extraction
Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood & Tissue kit (QIAGEN), according to manufacturer protocols

Healthy controls (comparator group)

As control group (CTRL), we will recruit a total of N=50 healthy subjects (never diagnosed with Sars-Cov2 infection) among the volunteer blood donors attending the U.O.C. Divisione di Immunologia Clinica, Immunoematologia, Medicina Trasfusionale e Immunologia dei Trapianti, Dipartimento di Medicina Interna e Specialistica, AOU, "L. Vanvitelli" University of Campania (Naples, Italy).

Biological: genomicDNA extraction
Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood & Tissue kit (QIAGEN), according to manufacturer protocols

COVID-19 patients compared with vaccinated subjects

Patients with previous Sars-CoV-2 infection who did not undergo vaccination; Patients with previous Sars-CoV-2 infection who undergone vaccination Subjects without previous Sars-CoV-2 infection who undergone vaccination

Diagnostic Test: Multitest 6 color TBNK and BD Lyotubes
The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells

Outcome Measures

Primary Outcome Measures

  1. Detection of Cellular-Mediated Immune Response [3 Months]

    The Investigators will perform the BD Multitest 6-color TBNK by using 50 uL of peripheral blood to detect the absolute number (N) of CD3+, CD19+, CD16+, CD46+, CD4+ and CD8+ cells.

  2. Detection of Cellular-Mediated Immune Response [3 Months]

    The Investigators will perform the BD™ Lyotubes kit by using 150 uL of peripheral blood to detect the absolute number (N) of CD4+ and CD8+ cells undergoing to differentiation from naive T cells to central memory, effector memory, and terminal memory

Secondary Outcome Measures

  1. Detection of T cell subpopulation maturation [5 months]

    The Investigators will perform the BD™ Lyotubes kit by using 150 uL of peripheral blood to detect the absolute number (N) of CD4+ and CD8+ cells undergoing to differentiation from naive T cells to central memory, effector memory, and terminal memory.

  2. Detection of T cell subpopulation maturation [5 months]

    The Investigators will perform the BD™ Lyotubes kit by using 150 uL of peripheral blood to detect the % of CD4+ and CD8+ cells undergoing to differentiation from naive T cells to central memory, effector memory, and terminal memory.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 18 years

  • Previous diagnosis of COVID-19

  • Absence of COVID-19 diagnosis

Exclusion Criteria:
  • Age <18 years

  • Inflammatory diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 U.O.C. Division of Clinical Immunology, Immunohematology, Transfusion Medicine and Transplant Immunology, Regional Reference Laboratory of Transplant Immunology, Department of Internal and Specialty Medicine, A.O.U., UniversityofCampania "Luigi Vanvitelli Napoli Italy 80138

Sponsors and Collaborators

  • University of Campania "Luigi Vanvitelli"

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Giuditta Benincasa, Principal Investigator, University of Campania "Luigi Vanvitelli"
ClinicalTrials.gov Identifier:
NCT04746521
Other Study ID Numbers:
  • L. Vanvitelli
First Posted:
Feb 9, 2021
Last Update Posted:
Feb 14, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 14, 2022